Equities

Oncology Institute Inc

TOI:NAQ

Oncology Institute Inc

Actions
Health CareHealth Care Providers
  • Price (USD)0.1515
  • Today's Change-0.004 / -2.26%
  • Shares traded5.96m
  • 1 Year change-92.46%
  • Beta0.4940
Data delayed at least 15 minutes, as of Nov 22 2024 17:55 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at 83 clinic locations across 15 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion and dispensary, radiation, programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. It also provides management services to 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.

  • Revenue in USD (TTM)378.93m
  • Net income in USD-57.46m
  • Incorporated2019
  • Employees800.00
  • Location
    Oncology Institute Inc18000 Studebaker Rd, Suite 800CERRITOS 90703United StatesUSA
  • Phone+1 (562) 735-3226
  • Fax+1 (302) 636-5454
  • Websitehttps://theoncologyinstitute.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Mangoceuticals Inc755.00k-9.33m6.22m----0.3986--8.23-5.88-5.880.45846.270.092117.97-----113.83---125.71--58.60---1,235.32--0.0653-18.830.0138--8,082.22---361.07------
ATI Physical Therapy Inc741.86m-79.62m6.66m6.00k------0.009-18.57-18.57174.1717.200.7625--8.02123,643.80-5.49---6.39--16.13---7.21----0.19050.8762--9.97--73.20------
Inspire Veterinary Partners Inc17.13m-19.33m7.10m156.00------0.4146-134.72-134.724.54-0.6310.816521.61246.52109,778.20-89.79---190.96--19.47---109.98--0.1311-2.741.20--69.56---206.68------
Ontrak Inc11.24m-35.68m7.72m102.00--0.5432--0.6868-10.55-10.553.023.370.5207--21.66110,186.30-123.82-54.80-228.86-73.3764.0053.50-237.77-71.95---2.270.4088---12.20-3.4439.08--99.58--
Univec Inc-100.00bn-100.00bn7.95m3.00---------------0.0113-----------50.96------17.47---198.310.0051-------74.07-64.8336.83------
Healthlynked Corp3.32m-6.19m9.14m38.00------2.75-0.0222-0.02220.0119-0.00690.786215.8281.3287,385.27-146.48-119.37-966.37-332.2247.3355.81-186.32-119.260.4586-4.69-----2.3220.4357.08---12.94--
Xcelerate Inc3.96m-296.19k9.90m1.00--7.12--2.50-0.0014-0.00140.01890.00321.516.133.90---11.334.24-49.19--71.7174.10-7.481.930.4797-0.82180.7237--6.6310.4317.00--174.06--
Pacific Health Care Organization Inc6.17m869.09k10.50m30.0012.090.921411.591.700.06780.06780.48120.890.5259--6.40205,557.707.417.297.937.8179.0382.7514.0913.28----0.00---2.00-3.7055.80-10.80-15.93--
Oncology Institute Inc378.93m-57.46m11.70m800.00--0.7565--0.0309-0.7706-0.77065.080.20491.9129.197.36473,666.30-35.34---44.12--14.1819.54-18.53-9.992.27-7.440.8553--28.4223.43-99,919.12--45.68--
Interpace Biosciences Inc44.89m4.89m11.80m108.002.43--2.290.2631.101.0610.13-2.533.1715.357.41415,675.9034.54-38.19---69.7360.4649.4410.88-41.010.52698.11----26.3112.93118.96--0.9184--
Aesthetic Medical Intl Hldg Grp Ltd(ADR)100.41m-6.69m11.96m1.29k--3.116.040.1191-0.1485-0.14852.210.08061.2920.8277.3678,081.45-9.06-23.36-35.45-48.5845.3955.32-7.02-23.720.2031-5.500.9581--1.86-2.1650.91--3.70--
Streamline Health Solutions Inc20.30m-18.82m12.75m77.00--12.03--0.628-0.3277-0.32770.34990.25110.4397--7.64263,636.40-40.77-22.06-56.63-31.6950.8649.96-92.72-54.55---4.460.4395---9.210.2057-64.31---11.72--
Psychemedics Corp.20.26m-3.00m13.79m116.00--2.53--0.6809-0.5142-0.51423.470.92381.69--5.12174,637.90-25.02-7.44-40.58-9.7038.3637.55-14.78-6.26---292.900.0969---12.45-12.33-283.21---33.32--
PharmChem Inc6.00m1.27m14.64m170.0011.554.7311.532.440.27270.27271.290.66611.677.238.04--35.37--44.59--64.09--21.17--4.45--0.00--3.50---16.95------
Data as of Nov 22 2024. Currency figures normalised to Oncology Institute Inc's reporting currency: US Dollar USD

Institutional shareholders

23.23%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Sep 20244.75m6.29%
Tiff Advisory Services LLCas of 30 Sep 20242.63m3.49%
Cincinnati Financial Corp. (Investment Portfolio)as of 30 Sep 20242.03m2.69%
Kent Lake Pr LLCas of 30 Sep 20242.00m2.65%
The Vanguard Group, Inc.as of 30 Sep 20241.76m2.34%
Kent Lake Capital LLCas of 30 Jun 20241.75m2.32%
Balyasny Asset Management LPas of 30 Sep 20241.73m2.29%
Geode Capital Management LLCas of 30 Sep 2024379.98k0.50%
FourWorld Capital Management LLCas of 30 Sep 2024257.00k0.34%
BlackRock Fund Advisorsas of 30 Sep 2024244.52k0.32%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.